AQR Capital Management
COGT icon

AQR Capital Management’s Cogent Biosciences COGT Stock Holding History

AQR Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.31M Buy
189,796
+67,996
+56% +$2.51M ﹤0.01% 1510
2025
Q4 		$4.33M Buy
121,800
+4,959
+4% +$139K ﹤0.01% 1659
2025
Q3 		$1.68M Buy
116,841
+71,760
+159% +$850K ﹤0.01% 2095
2025
Q2 		$324K Sell
45,081
-115,686
-72% -$641K ﹤0.01% 2834
2025
Q1 		$963K Buy
160,767
+133,174
+483% +$1.04M ﹤0.01% 2035
2024
Q4 		$215K Buy
27,593
+15,881
+136% +$158K ﹤0.01% 2646
2024
Q3 		$126K Buy
+11,712
New +$114K ﹤0.01% 2633
2023
Q3 		– Sell
-13,633
Closed -$161K – 2326
2023
Q2 		$161K Sell
13,633
-2,688
-16% -$30.8K ﹤0.01% 2105
2023
Q1 		$176K Sell
16,321
-7,228
-31% -$92.5K ﹤0.01% 2068
2022
Q4 		$272K Buy
+23,549
New +$292K ﹤0.01% 2003

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

AQR Capital Management's COGT Position: Q1 2026 in Review

AQR Capital Management increased its Cogent Biosciences (COGT) stake by 56% in Q1 2026, buying an estimated $2.51M and bringing the position to 189,796 shares worth $7.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

AQR Capital Management first reported a position in COGT in Q4 2022 and has held it in 10 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • AQR Capital Management held 189,796 shares of Cogent Biosciences worth $7.31M as of Q1 2026.
  • AQR Capital Management bought 67,996 Cogent Biosciences shares in Q1 2026, an estimated $2.51M.
  • Cogent Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1510 holding.
  • AQR Capital Management first reported a position in Cogent Biosciences in Q4 2022 and has held it in 10 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.